Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Molecular mechanisms of docetaxel resistance in prostate cancer
Y Sekino, J Teishima - Cancer Drug Resistance, 2020 - pmc.ncbi.nlm.nih.gov
Docetaxel (DTX) chemotherapy offers excellent initial response and confers significant
survival benefit in patients with castration-resistant prostate cancer (CRPC). However, the …
survival benefit in patients with castration-resistant prostate cancer (CRPC). However, the …
Molecular basis of drug resistance and insights for new treatment approaches in mCRPC
S Giacinti, G Poti, M Roberto, S Macrini… - Anticancer …, 2018 - ar.iiarjournals.org
Inhibiting androgen receptor (AR) signaling with androgen deprivation therapy (ADT)
represents the mainstay of therapy for advanced and metastatic prostate cancer. However …
represents the mainstay of therapy for advanced and metastatic prostate cancer. However …
AR-V7 exhibits non-canonical mechanisms of nuclear import and chromatin engagement in castrate-resistant prostate cancer
S Kim, CMC Au, MAB Jamalruddin, NE Abou-Ghali… - Elife, 2022 - elifesciences.org
Expression of the AR splice variant, androgen receptor variant 7 (AR-V7), in prostate cancer
is correlated with poor patient survival and resistance to AR targeted therapies and taxanes …
is correlated with poor patient survival and resistance to AR targeted therapies and taxanes …
Biomarkers of response to advanced prostate cancer therapy
ABSTRACT Introduction: Prostate cancer (PCa) is one of the most common adult
malignancies worldwide, and a major leading cause of cancer-related death in men in …
malignancies worldwide, and a major leading cause of cancer-related death in men in …
Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations
SA Patel, J Hoffman-Censits - OncoTargets and therapy, 2017 - Taylor & Francis
Cabazitaxel is an effective chemotherapeutic agent used in the treatment of metastatic
castration-resistant prostate cancer (mCRPC) refractory to docetaxel. With the advent of new …
castration-resistant prostate cancer (mCRPC) refractory to docetaxel. With the advent of new …
Prospective assessment of AR splice variant and PSMA detection on circulating tumor cells of mCRPC patients: preliminary analysis of patients enrolled in PRIMERA …
In our institution, a prospective observational trial testing micro-RNA (miRNA) and ARV7
mutational status in metastatic, castration resistant prostate cancer (mCRPC), is currently …
mutational status in metastatic, castration resistant prostate cancer (mCRPC), is currently …
Кабазитаксел в лечении кастрационно-резистентного рака: как найти баланс эффективности и безопасности?
МИ Волкова, ЯВ Гриднева, АС Ольшанская - Медицинский совет, 2019 - cyberleninka.ru
Кабазитаксел противоопухолевое средство из группы таксанов третьего поколения,
продемонстрировавшее эффективность при метастатическом кастрационно …
продемонстрировавшее эффективность при метастатическом кастрационно …